BeiGene, Ltd. (BGNE)

171.27 -6.72 (-3.78%) At close: 04:00PM EDT

BeiGene, Ltd.

Zhong-Guan-Cun Life Science Park
No.30 Science Park Road Changping District
Beijing 102206
China
86 01 0851 48500
https://www.beigene.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John V. Oyler	Co-Founder, Exec. Chairman & CEO	1.41M	N/A	1968
Dr. Xiaobin Wu Ph.D.	Pres, COO & GM of China	1.23M	N/A	1962
Dr. Xiaodong Wang Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director	4.25M	N/A	1963
Dr. Edna Huang M.D.	Consultant	749.55k	3.95M	1973
Ms. Julia Wang	CFO & Principal Accounting Officer	N/A	N/A	1971
Mr. Daniel Maller	VP of Fin. & Accounting	N/A	N/A	N/A
Ms. Mi Zhou	Sr. Director of Investor Relations	N/A	N/A	N/A
Mr. Kevin C. Mannix	Sr. VP of Investor Relations.	N/A	N/A	N/A
Mr. Scott Samuels	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Ms. Diana Lee Francis	VP and Global Head of Quality & Regulatory Compliance	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

Corporate Governance

BeiGene, Ltd.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.